Compare INTR & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INTR | IDYA |
|---|---|---|
| Founded | 1994 | 2015 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.6B |
| IPO Year | 2021 | 2019 |
| Metric | INTR | IDYA |
|---|---|---|
| Price | $5.44 | $36.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 16 |
| Target Price | $10.00 | ★ $52.86 |
| AVG Volume (30 Days) | ★ 5.4M | 1.3M |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.51% | N/A |
| EPS Growth | N/A | ★ 61.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $218,710,000.00 |
| Revenue This Year | $84.07 | N/A |
| Revenue Next Year | $18.26 | $201.05 |
| P/E Ratio | $16.39 | ★ N/A |
| Revenue Growth | N/A | ★ 3024.43 |
| 52 Week Low | $5.16 | $20.50 |
| 52 Week High | $10.36 | $39.28 |
| Indicator | INTR | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 34.93 | 72.78 |
| Support Level | N/A | $32.85 |
| Resistance Level | $6.10 | $38.15 |
| Average True Range (ATR) | 0.22 | 1.95 |
| MACD | 0.01 | 0.82 |
| Stochastic Oscillator | 22.34 | 83.38 |
Inter & Co Inc operates as a digital bank. The company's segment includes Banking & Spending; Investments; Insurance Brokerage; and Inter Shop. It generates maximum revenue from the Banking & Spending segment which comprises a wide range of banking products and services, such as checking accounts, cards, deposits, loans and advances, and other services, which are available to the clients by means of Inters mobile application.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.